12P A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs

Acquired resistance to EGFR TKI remains a significant barrier for patients with EGFR-mutated lung cancer, especially those without acquired EGFRT790M. The current study explored the safety and efficacy of combinational treatment atezolizumab, bevacizumab, pemetrexed-platinum in NSCLC after failure TKIs. activated mutations TKIs were recruited, T790M excluded. is combine bevacizumab (7.5 mg/kg), once every 3 weeks until progression. Endpoints ORR, PFS, OS. For comparison, we retrieved historical control group that enrolled who received plus single using from 2009 2020. This active recruiting still ongoing. Twenty enrolled, median age was 62 years. Seven had taken osimertinib before enrollment. PD-L1 expression ≧ 1% 35.0%. follow-up time 15.6 months. One patient excluded response analysis due idiopathic thrombocytopenic purpura being diagnosed 1st-cycle treatment. ORR 42.1%, DCR 100%. Median PFS 10.2 months, OS not mature yet. Patients have higher than < (85.7% vs. 16.7%; p = 0.003). Compared (Bev/Pem/Platin) (n 53), experimental (Atezo/Bev/Pem/Platin) showed benefits (100.0% 64.2%; 0.002) (10.2 5.9 mo.; 0.007). There no differences (42.1% 30.2%; 0.401) (unmatured 19.3 0.134). Grade adverse events occurred 40.0% (8/20) patients, 2 venous thromboembolism, 1 hydrocephalus, renal abscess. combination provided favorable failure. could be improved by addition atezolizumab.